VRTX
Vertex Pharmaceuticals Inc
$542.5-1.19%
Setup
①BreakoutBreakout
Buy Zone
$514.9-$540.65
Sector
Biotechnology
Industry
Biotechnology
51
Recommendation
Avoid
Avoid①
Breakout fired, but quality 51 (RS-based) < 70 — weak leadership, not a CAN-SLIM buy
VRTX chart
Loading chart…
ADX
Developing29.8Long Term
Up ↑Intermediate Term
Up ↑Short Term
Range →Overall Quality51
RS Rating
72
relative strength
Fundamentals
62
Solid fund-Q
Volume Demand
68
+101% vs avg
Technical Setup
75
6/8 checks
Industry/Theme
91
Biotechnology
Trade Plan
Avoid
Entry
$514.9
Entry Zone
$514.9-$540.65
Stop / Risk
$473.71
RS Rating
72
Volume confirmed
No
Targets
$617.88 / $643.63
Breakout · IBD Setup
4 ✓ 4 ✗
Entry $514.9–$540.65Stop $473.71Target $617.88 / $643.63
Market regimeRange
Quality51
RS Rating72
Above 50-MA+3.77%
Above 200-MA+12.75%
VolumeWeak
In Buy ZoneYes
Not extendedOK
Invalidation · Close below stop
How this came together
51
MarketRange
Setup①BreakoutBreakout
ConfidenceMedium · 476 trades · 38% win · +0.30R
Fund-Q62 · Solid
StatusAvoid①
Stock Data
52-Week Range407 – 569
Price % Chg YTD19.66%
Price % Chg 4wk7.29%
50-Day Avg Vol1.2 Mil
P/E Ratio32.5
Market Cap$142B
SectorHealthcare
IndustryBiotechnology
Company Fundamentals
EPS % Chg (Qtr)8.02%
Sales % Chg (Qtr)11.99%
EPS Growth 5y8.28%
Sales Growth 5y14.23%
Annual ROE23.54%
Gross Margin86.12%
Operating Margin39.54%
Net Margin34.69%
Debt / Equity0.10
Setup levels
Current price
$542.5
Pivot
$514.9
Distance to buy
-4.6%
52-week range
406.67-568.66
Trigger evidence
W double-bottom base
broke the middle peak 514.9 on volume ≥1.4×
Pattern levels: pivot 514.9
Financial health checks
5/5
Return on equity above 15%
ROE 23.54%
Net margin above 10%
Net margin 34.69%
EPS growing quarter on quarter
EPS q/q 8.02%
Sales growing quarter on quarter
Sales q/q 11.99%
Debt to equity below 1.0
D/E 0.10
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE23.54%
vs sector +0.9%
Net margin34.69%
vs sector +17.0%
Gross margin86.12%
vs sector +19.0%
EPS growth q/q8.02%
vs sector +0.4%
Sales growth q/q11.99%
vs sector -6.7%
Debt / equity0.10
vs sector -0.55
Business quality
62
GradeSolid
EPS rating38
P/E32.5
Market cap$142B
IndustryBiotechnology
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Pass
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-10-31
Trigger date
—
Days on list
6
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.